Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $15.33 Consensus PT from Brokerages

Posted by on Jul 9th, 2026

Coya Therapeutics, Inc. (NASDAQ:COYA – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $15.3333.

Several equities research analysts have recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a research note on Friday, April 10th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, March 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Monday, April 20th. Roth Capital initiated coverage on Coya Therapeutics in a research note on Friday, June 5th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Wall Street Zen cut Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th.

View Our Latest Analysis on COYA

Hedge Funds Weigh In On Coya Therapeutics

Several institutional investors have recently added to or reduced their stakes in COYA. Occudo Quantitative Strategies LP acquired a new stake in shares of Coya Therapeutics during the fourth quarter worth approximately $66,000. CIBC Private Wealth Group LLC bought a new position in shares of Coya Therapeutics in the fourth quarter valued at approximately $47,000. JPMorgan Chase & Co. acquired a new position in shares of Coya Therapeutics in the 3rd quarter worth approximately $28,000. Cetera Investment Advisers boosted its holdings in shares of Coya Therapeutics by 36.4% in the 1st quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock worth $118,000 after acquiring an additional 8,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Coya Therapeutics by 55.4% during the 1st quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock worth $410,000 after acquiring an additional 37,064 shares during the last quarter. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Stock Performance

NASDAQ:COYA opened at $5.36 on Thursday. The company has a 50-day moving average of $4.88 and a 200-day moving average of $4.76. Coya Therapeutics has a 52 week low of $3.71 and a 52 week high of $7.75. The company has a market capitalization of $125.75 million, a price-to-earnings ratio of -4.66 and a beta of 0.51.

Coya Therapeutics (NASDAQ:COYA – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. The business had revenue of $0.25 million for the quarter, compared to analysts’ expectations of $0.15 million. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%. Sell-side analysts forecast that Coya Therapeutics will post -1.49 EPS for the current year.

About Coya Therapeutics

(Get Free Report)

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

Featured Articles

Analyst Recommendations for Coya Therapeutics (NASDAQ:COYA)

Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.